-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add to the editor WeChat yxj_oncology to obtain) Key points The Lancet Oncol: Long-term colorectal cancer screening, the related mortality rate is significantly reduced.
JTO: KINDLE study results-Non-small cell lung cancer stage III patients in the real world Cancer Discovery: Anti-inflammatory drugs enhance the efficacy of immune checkpoint blockade by remodeling the tumor immune environment.
JTO: Sintilimab combined with platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small cells Lung cancer 01 The Lancet Oncol: Long-term screening for colorectal cancer, the related mortality rate has dropped significantly.
Recently, The Lancet Oncol published a study online that showed that the incidence, mortality and stage distribution of colorectal cancer in European countries showed different trends.
Colorectal cancer screening programs and popularity vary greatly among European countries.
The study aims to compare the relationship between the changes in the incidence, mortality and stage distribution of colorectal cancer in European countries over time and the implementation of colorectal cancer screening.
The screenshot of the article published since 2000 (most countries as of 2016), has included data on nearly 3.
1 million confirmed colorectal cancer patients in 21 European countries, and analyzed the age-standardized incidence and stage distribution of colorectal cancer patients over time The relationship of change.
The study calculated the combined incidence of various parts of the colon (proximal colon, distal colon, and rectum), estimated the average annual percentage change (AAPC) of morbidity and mortality, and performed a descriptive analysis of related patterns.
In countries that are rapidly achieving high coverage for colorectal cancer screening (Denmark, the Netherlands, and Slovenia), the age-standardized incidence rate initially increased, but then decreased.
On the contrary, in most countries where there is no large-scale implementation of colorectal cancer screening (Bulgaria, Estonia, Norway and Ukraine), the incidence of colorectal cancer has increased, and the AAPC of men has increased from 0.
3% (95% CI 0.
1-0.
5) to 1.
9% (95% CI 1.
2-2.
6), women increased from 0.
6% (95% CI 0.
4-0.
8) to 1.
1% (95% CI 0.
8-1.
4).
Countries that have long implemented colorectal cancer screening have the largest decline in mortality.
02JTO: KINDLE study results-real-world treatment patterns and clinical outcomes for stage III non-small cell lung cancer patients A few days ago, JTO published a study online that revealed the real-world stage III NSCLC treatment patterns and outcomes in the pre-immuno-oncology era Diversity.
Article release screenshots Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease that requires a multi-modal management method.
We conducted a real-world global study to observe the treatment patterns and related clinical outcomes of patients with stage III NSCLC.
KINDLE is a retrospective study of patients diagnosed with stage III NSCLC from January 2013 to December 2017, with at least 9 months of follow-up records since the first diagnosis.
In addition to descriptive statistics, the Kaplan-Meier method also estimates survival rates and calculates a two-sided 95% confidence interval (CI).
This study included 3151 patients from more than 100 research centers in 19 countries in Asia, the Middle East, Africa and Latin America.
The median age was 63.
0 years (range 21.
0-92.
0); 76.
5% were men, 69.
2% had a history of smoking, 53.
7% had adenocarcinoma, and 21.
4% had undergone radical resection.
Among more than 25 treatment options, concurrent chemoradiotherapy (cCRT) is the most common (29.
4%). The overall median progression-free survival (mPFS) and median overall survival (mOS) were 12.
5 months (95% CI 12.
06-13.
14) and 34.
9 months (95% CI 32.
00-38.
01), respectively.
We observed that mPFS and mOS were significantly correlated with gender, region, smoking or not, tumor stage, histology, and ECOG score (p<0.
05).
In univariate and multivariate analysis, patients with younger age, stage IIIA, better ECOG score, use of cCRT, and surgery as their initial treatment predicted better mOS.
Research suggests that there are still high unmet medical needs, and new methods are needed to further optimize the outcome.
03Cancer Discovery: Anti-inflammatory drugs may help enhance the efficacy of immune checkpoint blockade A few days ago, Cancer Discovery published a study online that clarified that the COX-2/PGE2/EP2-4 axis can be used as an independent immune checkpoint and treatment Strategies to quickly switch the tumor inflammation state from cold to hot.
Screenshots of the article release.
The formulation of strategies to improve the efficacy of immune checkpoint blockade (ICB) has always been a very important clinical need.
It is found that in mouse cancer models, widely used non-steroidal and steroidal anti-inflammatory drugs can be used in conjunction with ICB to target the COX-2/PGE2/EP2-4 pathway.
We used a bilateral surgical model to distinguish between responding and non-responding mice after treatment, and determined that acute interferon IFN-γ drives transcriptome remodeling in responding mice, which is also related to the benefit of patients in ICB treatment related.
Monotherapy with COX-2 inhibitors or EP2-4 PGE2 receptor antagonists can quickly induce a response, and the combination with ICB can increase the accumulation of effector T cells in the tumor.
By treating tumor fragments of patients with multiple cancer types, we found that similar changes in the tumor inflammatory environment are conducive to T cell activation.
04JTO: Sintilizumab combined with platinum and gemcitabine in the first-line treatment of advanced or metastatic squamous non-small cell lung cancer.
Recently, JTO published a study online.
In terms of progression-free survival (PFS), Sintilizumab combined Platinum/gemcitabine (GP) first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) has better clinical benefits than GP alone.
The toxicity is within the acceptable range, and no new unexpected safety risk signals have been observed.
Screenshot of the article release.
The standard chemotherapy for sqNSCLC includes platinum drugs plus gemcitabine.
In a phase Ib study, the anti-PD-1 antibody Sintilimab combined with GP as the first-line treatment of sqNSCLC showed significant efficacy.
To further compare the efficacy and safety of sintilimab and placebo combined with GP treatment.
ORIENT-12 is a randomized, double-blind, phase III study conducted in 42 centers in China to further compare the efficacy and safety of sintilimab and placebo in combination with GP.
This study included patients with locally advanced or metastatic sqNSCLC without EGFR sensitive mutations or ALK rearrangement.
Stratification factors include clinical stage, platinum drug selection, and PD-L1 tumor ratio score.
The blinded objects are patients, researchers, research staff, and the sponsor team.
Eligible patients were randomly divided into groups at a 1:1 ratio and received Sintilimab 200 mg or placebo combined with GP every 3 weeks for 4 or 6 cycles, and then received Sintilimab or placebo maintenance treatment , Until the disease progresses or the research time reaches 2 years.
The primary endpoint is progression-free survival (PFS).
From September 25, 2018 to July 26, 2019, a total of 543 patients were screened, of which 357 patients were randomly assigned to the Sintilimab-GP group (n=179) and the placebo-GP group ( n=178).
After a median follow-up of 12.
9 months, compared with the placebo-GP group, the sintilimab-GP group continued to show improvement in PFS, and the difference was statistically significant (HR: 0.
536; 95%CI 0.
422-0.
681; p< 0.
00001).
86.
6% of the patients in the Sintilimab-GP group and 83.
1% of the patients in the placebo-GP group had grade 3 or higher treatment-period adverse events (TEAE).
The incidence of TEAE leading to death in the two treatment groups was 4.
5% and 6.
7%, respectively. Reference: [1] 0864(21)02174-2/fulltext[3] Pelly Victoria S,Moeini Agrin,Roelofsen Lisanne M et al.
Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy.
[J] .
Cancer Discov, 2021, undefined: undefined.
[4] Caicun Zhou, Lin Wu, Yun Fan, Zhehai Wang, Lianke Liu, Gongyan Chen, Li Zhang, Dingzhi Huang, Shundong Cang, Zhixiong Yang, Jianying Zhou, Chengzhi Zhou, Baolan Li, Juan Li, Min Fan, Jiuwei Cui, Yuping Li, Hui Zhao, Jian Fang, Jianxin Xue, Chengping Hu, Ping Sun, Yingying Du, Hui Zhou, Shuyan Wang, Wen Zhang,Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind,phase 3 trial (ORIENT-12), Journal of Thoracic Oncology, 2021.
JTO: KINDLE study results-Non-small cell lung cancer stage III patients in the real world Cancer Discovery: Anti-inflammatory drugs enhance the efficacy of immune checkpoint blockade by remodeling the tumor immune environment.
JTO: Sintilimab combined with platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small cells Lung cancer 01 The Lancet Oncol: Long-term screening for colorectal cancer, the related mortality rate has dropped significantly.
Recently, The Lancet Oncol published a study online that showed that the incidence, mortality and stage distribution of colorectal cancer in European countries showed different trends.
Colorectal cancer screening programs and popularity vary greatly among European countries.
The study aims to compare the relationship between the changes in the incidence, mortality and stage distribution of colorectal cancer in European countries over time and the implementation of colorectal cancer screening.
The screenshot of the article published since 2000 (most countries as of 2016), has included data on nearly 3.
1 million confirmed colorectal cancer patients in 21 European countries, and analyzed the age-standardized incidence and stage distribution of colorectal cancer patients over time The relationship of change.
The study calculated the combined incidence of various parts of the colon (proximal colon, distal colon, and rectum), estimated the average annual percentage change (AAPC) of morbidity and mortality, and performed a descriptive analysis of related patterns.
In countries that are rapidly achieving high coverage for colorectal cancer screening (Denmark, the Netherlands, and Slovenia), the age-standardized incidence rate initially increased, but then decreased.
On the contrary, in most countries where there is no large-scale implementation of colorectal cancer screening (Bulgaria, Estonia, Norway and Ukraine), the incidence of colorectal cancer has increased, and the AAPC of men has increased from 0.
3% (95% CI 0.
1-0.
5) to 1.
9% (95% CI 1.
2-2.
6), women increased from 0.
6% (95% CI 0.
4-0.
8) to 1.
1% (95% CI 0.
8-1.
4).
Countries that have long implemented colorectal cancer screening have the largest decline in mortality.
02JTO: KINDLE study results-real-world treatment patterns and clinical outcomes for stage III non-small cell lung cancer patients A few days ago, JTO published a study online that revealed the real-world stage III NSCLC treatment patterns and outcomes in the pre-immuno-oncology era Diversity.
Article release screenshots Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease that requires a multi-modal management method.
We conducted a real-world global study to observe the treatment patterns and related clinical outcomes of patients with stage III NSCLC.
KINDLE is a retrospective study of patients diagnosed with stage III NSCLC from January 2013 to December 2017, with at least 9 months of follow-up records since the first diagnosis.
In addition to descriptive statistics, the Kaplan-Meier method also estimates survival rates and calculates a two-sided 95% confidence interval (CI).
This study included 3151 patients from more than 100 research centers in 19 countries in Asia, the Middle East, Africa and Latin America.
The median age was 63.
0 years (range 21.
0-92.
0); 76.
5% were men, 69.
2% had a history of smoking, 53.
7% had adenocarcinoma, and 21.
4% had undergone radical resection.
Among more than 25 treatment options, concurrent chemoradiotherapy (cCRT) is the most common (29.
4%). The overall median progression-free survival (mPFS) and median overall survival (mOS) were 12.
5 months (95% CI 12.
06-13.
14) and 34.
9 months (95% CI 32.
00-38.
01), respectively.
We observed that mPFS and mOS were significantly correlated with gender, region, smoking or not, tumor stage, histology, and ECOG score (p<0.
05).
In univariate and multivariate analysis, patients with younger age, stage IIIA, better ECOG score, use of cCRT, and surgery as their initial treatment predicted better mOS.
Research suggests that there are still high unmet medical needs, and new methods are needed to further optimize the outcome.
03Cancer Discovery: Anti-inflammatory drugs may help enhance the efficacy of immune checkpoint blockade A few days ago, Cancer Discovery published a study online that clarified that the COX-2/PGE2/EP2-4 axis can be used as an independent immune checkpoint and treatment Strategies to quickly switch the tumor inflammation state from cold to hot.
Screenshots of the article release.
The formulation of strategies to improve the efficacy of immune checkpoint blockade (ICB) has always been a very important clinical need.
It is found that in mouse cancer models, widely used non-steroidal and steroidal anti-inflammatory drugs can be used in conjunction with ICB to target the COX-2/PGE2/EP2-4 pathway.
We used a bilateral surgical model to distinguish between responding and non-responding mice after treatment, and determined that acute interferon IFN-γ drives transcriptome remodeling in responding mice, which is also related to the benefit of patients in ICB treatment related.
Monotherapy with COX-2 inhibitors or EP2-4 PGE2 receptor antagonists can quickly induce a response, and the combination with ICB can increase the accumulation of effector T cells in the tumor.
By treating tumor fragments of patients with multiple cancer types, we found that similar changes in the tumor inflammatory environment are conducive to T cell activation.
04JTO: Sintilizumab combined with platinum and gemcitabine in the first-line treatment of advanced or metastatic squamous non-small cell lung cancer.
Recently, JTO published a study online.
In terms of progression-free survival (PFS), Sintilizumab combined Platinum/gemcitabine (GP) first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) has better clinical benefits than GP alone.
The toxicity is within the acceptable range, and no new unexpected safety risk signals have been observed.
Screenshot of the article release.
The standard chemotherapy for sqNSCLC includes platinum drugs plus gemcitabine.
In a phase Ib study, the anti-PD-1 antibody Sintilimab combined with GP as the first-line treatment of sqNSCLC showed significant efficacy.
To further compare the efficacy and safety of sintilimab and placebo combined with GP treatment.
ORIENT-12 is a randomized, double-blind, phase III study conducted in 42 centers in China to further compare the efficacy and safety of sintilimab and placebo in combination with GP.
This study included patients with locally advanced or metastatic sqNSCLC without EGFR sensitive mutations or ALK rearrangement.
Stratification factors include clinical stage, platinum drug selection, and PD-L1 tumor ratio score.
The blinded objects are patients, researchers, research staff, and the sponsor team.
Eligible patients were randomly divided into groups at a 1:1 ratio and received Sintilimab 200 mg or placebo combined with GP every 3 weeks for 4 or 6 cycles, and then received Sintilimab or placebo maintenance treatment , Until the disease progresses or the research time reaches 2 years.
The primary endpoint is progression-free survival (PFS).
From September 25, 2018 to July 26, 2019, a total of 543 patients were screened, of which 357 patients were randomly assigned to the Sintilimab-GP group (n=179) and the placebo-GP group ( n=178).
After a median follow-up of 12.
9 months, compared with the placebo-GP group, the sintilimab-GP group continued to show improvement in PFS, and the difference was statistically significant (HR: 0.
536; 95%CI 0.
422-0.
681; p< 0.
00001).
86.
6% of the patients in the Sintilimab-GP group and 83.
1% of the patients in the placebo-GP group had grade 3 or higher treatment-period adverse events (TEAE).
The incidence of TEAE leading to death in the two treatment groups was 4.
5% and 6.
7%, respectively. Reference: [1] 0864(21)02174-2/fulltext[3] Pelly Victoria S,Moeini Agrin,Roelofsen Lisanne M et al.
Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy.
[J] .
Cancer Discov, 2021, undefined: undefined.
[4] Caicun Zhou, Lin Wu, Yun Fan, Zhehai Wang, Lianke Liu, Gongyan Chen, Li Zhang, Dingzhi Huang, Shundong Cang, Zhixiong Yang, Jianying Zhou, Chengzhi Zhou, Baolan Li, Juan Li, Min Fan, Jiuwei Cui, Yuping Li, Hui Zhao, Jian Fang, Jianxin Xue, Chengping Hu, Ping Sun, Yingying Du, Hui Zhou, Shuyan Wang, Wen Zhang,Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind,phase 3 trial (ORIENT-12), Journal of Thoracic Oncology, 2021.
